| Retinoic acid syndrome. Recognition, prevention and management. | |
| | |
MedLine Citation:
|
PMID: 9565738 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The introduction of treatment with tretinoin (all-trans retinoic acid) and its combination with antineoplastic therapy has improved the outcome of acute promyelocytic leukaemia (APL). Retinoic acid syndrome is the major adverse effect of tretinoin and it occurs in about 25% of treated APL patients in the absence of prophylactic measures and is often fatal. Generally, the retinoic acid syndrome is associated with increasing leucocyte counts and is probably caused by the release of several cytokines by maturing blast cells. The retinoic acid syndrome gives a clinical picture of bodyweight gain, respiratory distress, serous effusions and cardiac and renal failure. Adequate prophylaxis, based on the addition to tretinoin of dexamethasone and also, according to most authors, antineoplastic therapy (in case of rapidly increasing leucocyte counts) has decreased the incidence of retinoic acid syndrome to about 15%. Most importantly, these measures have reduced its mortality to about 1% of all treated patients. |
| | |
Authors:
|
P Fenaux; S De Botton |
Related Documents
:
|
8024798 - Chronic topical application of all-trans-retinoic acid in man does not affect corneocyt... 12235288 - Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vi... 19106468 - Effects of sodium bicarbonate on butyric acid-induced epithelial cell damage in vitro. 2190178 - Retinoic acids in the treatment of acute promyelocytic leukemia. 8735518 - Changes in the release of amino acid neurotransmitters in the brains of calves and shee... 10699748 - Different roles for nitrogen monoxide and peroxynitrite in lipid peroxidation induced b... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drug safety : an international journal of medical toxicology and drug experience Volume: 18 ISSN: 0114-5916 ISO Abbreviation: Drug Saf Publication Date: 1998 Apr |
Date Detail:
|
Created Date: 1998-06-11 Completed Date: 1998-06-11 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9002928 Medline TA: Drug Saf Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 273-9 Citation Subset: IM |
Affiliation:
|
Service des Maladies du Sang, CHU, Lille, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents
/
therapeutic use* Antineoplastic Agents / adverse effects* Clinical Trials as Topic Cytokines / metabolism* Dexamethasone / therapeutic use* Heart Failure / chemically induced, prevention & control Humans Infant, Newborn Kidney Failure / chemically induced, prevention & control Leukemia, Promyelocytic, Acute / complications, drug therapy Leukocyte Count / drug effects Respiratory Distress Syndrome, Newborn / chemically induced, prevention & control Syndrome Tretinoin / adverse effects* Weight Gain / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antineoplastic Agents; 0/Cytokines; 302-79-4/Tretinoin; 50-02-2/Dexamethasone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.
Next Document: Safety review of adult clinical trial experience with lamotrigine.